EVP, Head of US Oncology · INCYTE CORP · INCYTE CORP — Employee Stock Option (right to buy)
Side
A
Value
—
Shares
14.2K
Price
—
Executed
Jan 16, 2026
Disclosed
Jan 21, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Jan 16 executedJan 21, 2026 disclosed
INCY · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 3 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
INCYTE CORP — Employee Stock Option (right to buy)
Ticker
INCY
Shares
14.2K
Price per share
$0
Execution date (reported)
Jan 16, 2026
Owned after transaction
14.2K shares
Days from execution to publication
5
What this establishes
Issa Mohamed Khairie filed this Form 4 reporting a grant or award of INCY on Jan 16, 2026. It became public on Jan 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, Head of US Oncology
Issa Mohamed Khairiecik:0002050035
Issuer
INCYTE CORPcik:0000879169
Revision history · 0
No field has changed since this record was first ingested.
